Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development ...
TipRanks on MSN
Exicure announces near-term strategic priorities
Exicure’s (XCUR) ongoing Phase 2 study is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist, in ...
Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism First-in-human findings with ...
Clinical data from independent investigator-initiated studies using [68Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary AldosteronismFirst-in-human findings with [¹77Lu]Lu-Pentix ...
Exicure Highlights Recent Achievements And Near-Term Strategic Priorities. Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and ...
The CXCR inhibitor market is expanding steadily as interest in targeted oncology and immuno-oncology treatments grows. Rising ...
Favorable safety profile enables advancement of radiolabeled PentixaTher to fourth of five planned activity dose levels in investigator-initiated PENTILULA Phase 1/2 trial Milestone marks important ...
Department of Chemistry and Centre for Biomedical Research, University of Hull, Hull, HU6 7RX, U.K., Department of Chemistry and Physics, Southwestern Oklahoma State University, 100 Campus Drive, ...
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced a strategic restructuring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback